
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
The positive outlook for enGene Holdings Inc. is largely driven by the strong clinical results of detalimogene, which show a six-month complete response (CR) rate that meets the standards of leading competitors while benefiting from a non-viral delivery system. The recent protocol amendments have significantly improved CR rates, aligning them with the best-in-class assets, thereby enhancing investor expectations and confidence in the product's market potential. Moreover, the company has adjusted its discounted cash flow (DCF)-derived price target upward, indicative of increased conviction in the projected sales, which are anticipated to reach $530 million by 2031.
Bears say
The financial outlook for enGene Holdings Inc is negatively impacted by several key factors. First, the disappointment in Detalimogene's performance during the LEGEND trial, indicated by lower complete response (CR) rates compared to earlier data, raises concerns about the viability of achieving regulatory approval, which is further complicated by changing regulatory requirements and unforeseen competition from more established companies in the biotechnology field. Additionally, the company is likely facing higher-than-expected capital requirements, leading to an anticipation of equity dilution, which could diminish shareholder value and adversely affect its ability to fund ongoing drug development.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares